Anticonvulsant therapy suicide risk in affective disorders

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 2, 1999, Pages 89-93

  Goodwin, Frederick K ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b Neurosci Res Ctr Natl I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM;

AFFECTIVE NEUROSIS; ANTICONVULSANT THERAPY; ANXIETY; CONFERENCE PAPER; DEPRESSION; HUMAN; INSOMNIA; PANIC; PRIORITY JOURNAL; RISK FACTOR; SUBSTANCE ABUSE; SUICIDE;

AMITRIPTYLINE; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LITHIUM; MALE; MOOD DISORDERS; PROSPECTIVE STUDIES; RISK FACTORS; SUICIDE; TRIAZINES; VALPROIC ACID;

EID: 0032994973     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Barraclough B, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974;125:355-373
2. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
3. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970;2:326-330
4. Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 1997;836: 339-351
5. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47:490-494
6. Watkins SE, Callendar K, Thomas DR, et al. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987;150: 180-182
7. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204
8. Bellaire W, Demisch K, Stoll K. Carbamazepine vs lithium in prophylaxis of recurrent affective disorders. Psychopharmacology (Berl) 1988;96 (suppl):287
9. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85: 114-118
10. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
11. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48: 62-68
12. McElroy SL, Keck PE Jr, Tugrul KC, et al. Valproate as a loading treatment in acute mania. Neuropsychobiology 1993;27:146-149
13. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989;50(3, suppl):35-39
14. Lambert PA, Venaud G. Use of valpromide in psychiatric therapeutics. Encephale 1987;13:367-373
15. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29:103-107
16. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
17. Fawcett J, Scheftner W, Clark D, et al. Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study. Am J Psychiatry 1987;144:35-40
18. De Deyn PP, Macdonald RL. Effects of antiepileptic drugs on GABA responses and on reduction of GABA responses by PTZ and DMCM on mouse neurons in cell culture. Epilepsia 1989;30:17-25
19. Concas A, Mascia MP, Sanna E, et al. "In vivo" administration of valproate decreases t-[35S]butylbicyclophosphorothionate binding in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1991;343:296-300
20. Motohashi N. GABA receptor alterations after chronic lithium administration: comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:571-579
21. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983;18:451-466
22. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-111
23. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229-233
24. Prien RF, Caffey EM Jr, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis: report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974;31:189-192
25. Kukopulos A, Caliari B, Tundo A. Rapid cyclers, temperament and antidepressants. Compr Psychiatry 1983;24:249-258
26. DiCostanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand 1991;83:456-459
27. Calabrese JR, Rapport DJ, Kimmel SE, et al. Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry 1993;38(suppl 2): S57-S61
28. Nilsson A. Lithium therapy and suicide risk. J Clin Psychiatry 1999;60: (suppl 2):85-88
29. Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995;56:118-121
30. Meltzer HY. Serotonergic dysfunction in depression. Br J Psychiatry 1989; 155(suppl 8):25-31
31. Mann JJ, Oquendo M, Underwood MD, et al. The neurobiology of suicide risk: a review for the clinician. J Clin Psychiatry 1999;60(suppl 2):7-11
32. Arora RC, Meltzer HY. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 1989;146:730-736
33. Maes M, Scharpe S, Verkerk R, et al. Seasonal variation in plasma L-tryptophan availability in healthy volunteers: relationships to violent suicide occurrence. Arch Gen Psychiatry 1995;52:937-946
34. Brown GL, Goodwin FK, Ballenger JC, et al. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1: 131-139
35. Goodwin FK, Brown GL. Biological correlates of human aggression and suicide. Int J Neurosci 1986;31:252
36. Treiser SL, Cascio CS, O'Donohue TL, et al. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science 1981;213:1529-1531
37. Maes M, Calabrese JR, Jayathilake K, et al. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 1997; 71:67-76
38. Lee HK, Reddy TB, Travin S, et al. A trial of lithium citrate for the management of acute agitation of psychiatric inpatients: a pilot study [letter]. J Clin Psychopharmacol 1992;12:361-362
39. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988;45:111-119
40. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448-451
41. Zayas EM, Grossberg GT. Treating the agitated Alzheimer patient. J Clin Psychiatry 1996;57(suppl 7):46-51
42. Horne M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. J Clin Psychiatry 1995;56:430-431
43. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997
44. Singh L, Field MJ, Ferris P, et al. The antiepileptic agent gahapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996;127:1-9
45. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder [letter]. Am J Psychiatry 1997;154:291-292
46. Young LT, Robb J, Patelis-Siotis I, et al. Gabapentin in bipolar disease: a case series. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR452:190
47. Ryback RS, Brodsky L, Munasifi F. Gabapentin in bipolar disorder [letter]. J Neuropsychiatry Clin Neurosci 1997;9:301
48. McElroy SL, Soutullo CA, Keck PE Jr, et al. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9:99-103
49. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185-189
50. Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder [letter]. J Clin Psychiatry 1997;58:271-273
51. Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:522-527
52. Corn T, Ascher J, Calabrese JR, et al. Lamictal in the treatment of bipolar disorder. In: Scientific Abstracts of the 35th Annual Meeting of the American College of Neuropsychopharmacology; December 9-13, 1996; San Juan, Puerto Rico; 222
53. Post RM, Leverich GS, Denicoff KD, et al. Alternative approaches to refractory depression in bipolar illness. Depress Anxiety 1997;5:175-189
54. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21